Page 2 - Cassava Sciences News Today

The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava ...

NEW YORK, March 29, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. and reminds investors of the...

NEW YORK, March 27, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. . The class action, filed in the United States District...

/PRNewswire/ -- (PRNEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company")...

NEW YORK, March 27, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor...

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between...

IMMINENT SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava ...

Corporate Overview First Quarter 2024 Forward-Looking Statements & Other Notices Cassava Sciences is in the business of new drug discovery...

An Independent Data and Safety Monitoring Board Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials...